ALNYLAM PHARMACEUTICALS INC (ALNY) Stock News
NASDAQ:ALNY - Nasdaq - US02043Q1076 - Common Stock - Currency: USD
ALNY Latest News, Press Relases and Analysis
TransCon® hGH Boosts TransCon® CNP Results in Kids with Achondroplasia by Week 26
Ascendis Pharma A/S (NASDAQ:ASND) is among the 13 Biotech Stocks with Huge Upside Potential. It reported interim Week 26 data from its Phase 2 COACH Trial, confirming that combining TransCon hGH (lonapegsomatropin) with TransCon CNP (navepegritide) raised annualized growth velocity (AGV) and height Z-scores in children with achondroplasia. A mean AGV of 9.14 cm/year and […]
Analyst Kelly Shi from Jefferies Maintained a Buy Rating on Insmed Incorporated (INSM)
Insmed Incorporated (NASDAQ:INSM) is among the 13 Biotech Stocks with Huge Upside Potential. Kelly Shi of Jefferies has given Insmed Incorporated (NASDAQ:INSM) a buy recommendation, stating that she is confident in the TPIP treatment’s impending Phase 2 data for pulmonary arterial hypertension. Shi anticipates a substantial decrease in pulmonary vascular resistance, the main outcome of […]
Should Invesco NASDAQ Next Gen 100 ETF (QQQJ) Be on Your Investing Radar?
Style Box ETF report for QQQJ
US Appeals Court Confirms Patent Validity of Acadia’s Parkinson’s Medication
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is among the 13 Biotech Stocks with Huge Upside Potential. It declared that the U.S. Court of Appeals maintained the legality of its composition of matter patent for the medication Nuplazid, which treats psychosis in Parkinson’s disease. The verdict supports ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) in its legal struggle with India-based MSN […]
The European Commission Approves Alnylam’s AMVUTTRA
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the 13 Biotech Stocks with Huge Upside Potential. It declared on June 9, 2025, that AMVUTTRA® (vutrisiran) has been approved by the European Commission to treat wild-type or hereditary ATTR amyloidosis with cardiomyopathy (ATTR-CM). As a result, AMVUTTRA is the first and only RNAi treatment approved in the […]
Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program
Mentions: TIL
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
Smart Beta ETF report for XBI
Insmed surges on lung drug data; Recursion cuts staff
Insmed shares rocketed on results for a pulmonary arterial hypertension drug that exceeded Wall Street expectations. Elsewhere, Recursion is laying off 20% of its workforce and Gilead halted several HIV studies.
Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy
The FDA granted Sarepta’s rAAVrh74 Viral Vector a Platform Technology Designation
The FDA has designated the viral vector rAAVrh74, which Sarepta Therapeutics, Inc. (NASDAQ:SRPT) uses in its gene therapy candidate SRP-9003 for limb-girdle muscular dystrophy type 2E/R4 (LGMD2E/R4), as a platform technology. Future approvals of treatments utilizing the same delivery technology might be accelerated by this designation. Phase III EMERGENE studies for SRP-9003, sometimes referred to […]
Why Is Sarepta Therapeutics (SRPT) Up 7.7% Since Last Earnings Report?
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Mentions: SRPT
Alnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare Conference
Is Intel Corp Stock a Buy?
Intel stock has sharply lagged its sector, slumping 32% over the past year. The past few years have been difficult -- to say the least -- for Intel (NASDAQ: INTC). Competitors like Nvidia have seen their share prices balloon thanks to the rapid rise of AI technologies.
SolarEdge upgraded to Market Perform from Underperform at Northland
Northland upgraded SolarEdge (SEDG) to Market Perform from Underperform with an unchanged price target of $15.50. Shares have declined meaningfully since the firm’s downgrade on May 16, notes the analyst, who argues that regardless of what legislation ultimately looks like, utility-scale solar is “the cheapest and fastest way to add generation capacity” and SolarEdge is well-positioned as a non-Chinese supplier with cybersecurity capabilities. Published first on TheFly – the ultimate source for
3 Reasons to Buy This Artificial Intelligence (AI) Stock Like There Is No Tomorrow
Meta Platforms has a vast ecosystem to monetize in the AI race. The company is investing heavily in AI-related infrastructure. Artificial intelligence (AI) isn't new, but novel applications of the technology have become extremely popular in the past few years.
3 High-Flying Stocks That Could Soar Even More
Alnylam Pharmaceuticals has had a lot of excitement this year, with more good news potentially on the way. Summit Therapeutics could keep its momentum going with positive clinical results for cancer drug ivonescimab. Here's why they picked Alnylam Pharmaceuticals (NASDAQ: ALNY), Axsome Therapeutics (NASDAQ: AXSM), and Summit Therapeutics (NASDAQ: SMMT).
Target Stock: Time to Panic?
Target missed estimates and cut its guidance in its first-quarter earnings report. Target (NYSE: TGT) has been one of the most disappointing retail stocks on the market recently. After another earnings report came in well below both analysts' and the company's expectations, Target seems as far away from a recovery as ever.
Alnylam Issues 2024 Corporate Responsibility Report
Snowflake Inc. (SNOW): Among the Best Growth Stocks to Buy and Hold for the Long Term
We recently compiled a list of the 12 Best Growth Stocks to Buy and Hold for the Long Term. In this article, we are going to take a look at where Snowflake Inc. (NYSE:SNOW) stands against the other growth stocks. What’s the Bull Case for US Equities? The market closed last week mostly lower, however, the […]
BioNTech SE (BNTX): Among the Best Growth Stocks to Buy and Hold for the Long Term
We recently compiled a list of the 12 Best Growth Stocks to Buy and Hold for the Long Term. In this article, we are going to take a look at where BioNTech SE (NASDAQ:BNTX) stands against the other growth stocks. What’s the Bull Case for US Equities? The market closed last week mostly lower, however, the […]
The inflation fight isn't over. Forecasters expect tariffs to show up in prices as soon as next month
Inflation could rise this summer as tariffs are reflected in the data, forecasters say. The US tariff rate is high even after the latest deal with China.
Alnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 Congress
Why Sarepta Therapeutics, Inc. (SRPT) Nosedived on Wednesday
We recently published an article titled Why These 10 Firms Nosedived Today. In this article, we are going to take a look at where Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stands against the other stocks. The stock market bounced back from the previous day’s losses, with all major indices finishing higher as investors cheered the central bank’s decision to […]
Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference
Compared to Estimates, Alnylam (ALNY) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Alnylam (ALNY) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates
Alnylam (ALNY) delivered earnings and revenue surprises of 98.21% and 1.02%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: TGTX
Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress
MiMedx (MDXG) Q1 Earnings Match Estimates
MiMedx (MDXG) delivered earnings and revenue surprises of 0% and 2.56%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: MDXG